Actively Recruiting
Safety, Tolerability, and Efficacy Study of ALXN2350 Gene Therapy in Adults with BAG3-Associated Dilated Cardiomyopathy
Led by Alexion Pharmaceuticals, Inc. · Updated on 2026-08-28
6
Participants Needed
11
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, and effectiveness of ALXN2350 gene therapy in adults with BAG3 mutation associated dilated cardiomyopathy DCM. This Phase 12 open-label study focuses on finding the appropriate dose and expanding the dose range in this population with a specific heart condition linked to a genetic mutation. Participants will receive a single intravenous infusion of ALXN2350, a gene therapy product containing an AAV9 capsid with the BAG3 transgene. The dose varies depending on the cohort, with three different dose levels under study to determine safety and appropriate dosing. During the study, participants will be monitored for adverse events and cardiac health outcomes over time, with assessments up to 78 weeks. These include evaluations of serious side effects, heart function, cardiac events, and biomarkers related to heart failure. The study spans from initial treatment through long-term follow-up to assess the therapys impact and safety.
CONDITIONS
Brief Title
ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy
Research Team
A
Alexion Pharmaceuticals, Inc. (Sponsor)
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here